TMB-H + PD-L1 expression	Triple Negative Breast Cancer	TMB-H + PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
TMB-H + PD-L1 expression	Urothelial Cancer	TMB-H + PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
TMB-H + PD-L1 expression	Small Cell Lung Cancer	TMB-H + PD-L1 expression	Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
TMB-H + PD-L1 expression	Urothelial Cancer	TMB-H + PD-L1 expression	Urothelial Cancer	durvalumab + tremelimumab Sensitive: C3 – Early Trials durvalumab + tremelimumab Sensitive : C3	durvalumab + tremelimumab Sensitive: C3 – Early Trials durvalumab + tremelimumab Sensitive : C3
TMB-H + PD-L1 expression	Urothelial Cancer	TMB-H + PD-L1 expression	Urothelial Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TMB-H + PD-L1 expression	Colorectal Cancer	TMB-H + PD-L1 expression	Colorectal Cancer	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3
TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C3 – Early Trials anlotinib + sintilimab Sensitive : C3	anlotinib + sintilimab Sensitive: C3 – Early Trials anlotinib + sintilimab Sensitive : C3
TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
TMB-H + PD-L1 expression	Penile Cancer	TMB-H + PD-L1 expression	Penile Cancer	toripalimab-tpzi Sensitive: C4 – Case Studies toripalimab-tpzi Sensitive : C4	toripalimab-tpzi Sensitive: C4 – Case Studies toripalimab-tpzi Sensitive : C4
TMB-H + PD-L1 expression	Squamous Cell Skin Cancer	TMB-H + PD-L1 expression	Squamous Cell Skin Cancer	pembrolizumab + panitumumab Sensitive: C4 – Case Studies pembrolizumab + panitumumab Sensitive : C4	pembrolizumab + panitumumab Sensitive: C4 – Case Studies pembrolizumab + panitumumab Sensitive : C4
TMB-H + PD-L1 expression	Urothelial Cancer	TMB-H + PD-L1 expression	Urothelial Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
TMB-H + PD-L1 expression	Soft Tissue Sarcoma	TMB-H + PD-L1 expression	Soft Tissue Sarcoma	anlotinib + toripalimab-tpzi Sensitive: C4 – Case Studies anlotinib + toripalimab-tpzi Sensitive : C4	anlotinib + toripalimab-tpzi Sensitive: C4 – Case Studies anlotinib + toripalimab-tpzi Sensitive : C4
TMB-H + PD-L1 expression	Lung Cancer	TMB-H + PD-L1 expression	Lung Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4

TMB-H + PD-L1 expression

Associations